{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T05:38:26Z","timestamp":1769578706822,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,20]]},"DOI":"10.7759\/cureus.71913","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T10:40:36Z","timestamp":1729420836000},"source":"Crossref","is-referenced-by-count":1,"title":["Exploring Therapeutic Strategies for Pediatric Cystic Fibrosis: An In-Depth Comparative Review"],"prefix":"10.7759","author":[{"given":"Alisha","family":"Lakhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchira","family":"Clementina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Siddiqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailee","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sravani","family":"Bhavanam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitrey Hareshkumar","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhoomi","family":"Bagadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Usman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mishal Mohammed","family":"Koyappathodi Machingal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankush","family":"Kimmatkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Chunawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harpratap","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasim","family":"Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhavi","family":"Katta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000515540.36581.92","article-title":"Keep them breathing: cystic fibrosis pathophysiology, diagnosis, and treatment","volume":"30","author":"Brown SD","year":"2017","unstructured":"Brown SD, White R, Tobin P. Keep them breathing: cystic fibrosis pathophysiology, diagnosis, and treatment. JAAPA. 2017, 30:23-7. 10.1097\/01.JAA.0000515540.36581.92","journal-title":"JAAPA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn JS","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016, 388:2519-31. 10.1016\/S0140-6736(16)00576-6","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe SM","year":"2005","unstructured":"Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005, 352:1992-2001. 10.1056\/NEJMra043184","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen F","year":"2015","unstructured":"Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers. 2015, 1:10. 10.1038\/nrdp.2015.10","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","unstructured":"Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Cystic Fibrosis Foundation. (2019). Accessed. October 10, 2024: https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2018-Annual-Report.pdf.."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2393-9","article-title":"Cystic fibrosis: a clinical view","volume":"74","author":"Castellani C","year":"2017","unstructured":"Castellani C, Assael BM. Cystic fibrosis: a clinical view. Cell Mol Life Sci. 2017, 74:129-40. 10.1007\/s00018-016-2393-9","journal-title":"Cell Mol Life Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.9b01384","article-title":"Mode of nitric oxide delivery affects antibacterial action","volume":"6","author":"Hall JR","year":"2020","unstructured":"Hall JR, Rouillard KR, Suchyta DJ, Brown MD, Ahonen MJ, Schoenfisc MH. Mode of nitric oxide delivery affects antibacterial action. ACS Biomater Sci Eng. 2020, 6:433-41. 10.1021\/acsbiomaterials.9b01384","journal-title":"ACS Biomater Sci Eng"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study","volume":"56","author":"Andersen DH","year":"1938","unstructured":"Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathologic study. Am J Dis Child. 1938, 56:344-99. 10.1001\/archpedi.1938.01980140114013","journal-title":"Am J Dis Child"},{"key":"ref9","article-title":"Physiotherapy in cystic fibrosis","volume":"93","author":"Prasad SA","year":"2000","unstructured":"Prasad SA, Tannenbaum EL, Mikelsons C. Physiotherapy in cystic fibrosis. J R Soc Med. 2000, 93:27-36.","journal-title":"J R Soc Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/genes11040401","article-title":"The impact of the CFTR gene discovery on cystic fibrosis diagnosis, counseling, and preventive therapy","volume":"11","author":"Farrell PM","year":"2020","unstructured":"Farrell PM, Rock MJ, Baker MW. The impact of the CFTR gene discovery on cystic fibrosis diagnosis, counseling, and preventive therapy. Genes (Basel). 2020, 11:401. 10.3390\/genes11040401","journal-title":"Genes (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20873","article-title":"Shifting patterns of inhaled antibiotic use in cystic fibrosis","volume":"43","author":"Moskowitz SM","year":"2008","unstructured":"Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al.. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol. 2008, 43:874-81. 10.1002\/ppul.20873","journal-title":"Pediatr Pulmonol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23897","article-title":"Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change","volume":"53","author":"VanDevanter DR","year":"2018","unstructured":"VanDevanter DR, Craib ML, Pasta DJ, Millar SJ, Morgan WJ, Konstan MW. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatr Pulmonol. 2018, 53:43-9. 10.1002\/ppul.23897","journal-title":"Pediatr Pulmonol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1547347","article-title":"Lung transplantation for cystic fibrosis: results, indications, complications, and controversies","volume":"36","author":"Lynch JP 3rd","year":"2015","unstructured":"Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med. 2015, 36:299-320. 10.1055\/s-0035-1547347","journal-title":"Semin Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso FJ","year":"2010","unstructured":"Accurso FJ, Rowe SM, Clancy JP, et al.. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010, 363:1991-2003. 10.1056\/NEJMoa0909825","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright CE","year":"2015","unstructured":"Wainwright CE, Elborn JS, Ramsey BW, et al.. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015, 373:220-31. 10.1056\/NEJMoa1409547","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia S","year":"2023","unstructured":"Jia S, Taylor-Cousar JL. Cystic fibrosis modulator therapies. Annu Rev Med. 2023, 74:413-26. 10.1146\/annurev-med-042921-021447","journal-title":"Annu Rev Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01429","article-title":"Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine","volume":"9","author":"Awatade NT","year":"2018","unstructured":"Awatade NT, Wong SL, Hewson CK, Fawcett LK, Kicic A, Jaffe A, Waters SA. Human primary epithelial cell models: promising tools in the era of cystic fibrosis personalized medicine. Front Pharmacol. 2018, 9:1429. 10.3389\/fphar.2018.01429","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20212006","article-title":"Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy","volume":"42","author":"Farinha CM","year":"2022","unstructured":"Farinha CM, Callebaut I. Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy. Biosci Rep. 2022, 42:6. 10.1042\/BSR20212006","journal-title":"Biosci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1694021","article-title":"Cystic fibrosis: pathophysiology of lung disease","volume":"40","author":"Bergeron C","year":"2019","unstructured":"Bergeron C, Cantin AM. Cystic fibrosis: pathophysiology of lung disease. Semin Respir Crit Care Med. 2019, 40:715-26. 10.1055\/s-0039-1694021","journal-title":"Semin Respir Crit Care Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.05.034","article-title":"Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy","volume":"45","author":"Lubamba B","year":"2012","unstructured":"Lubamba B, Dhooghe B, Noel S, Leal T. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem. 2012, 45:1132-44. 10.1016\/j.clinbiochem.2012.05.034","journal-title":"Clin Biochem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31818e55a2","article-title":"Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders","volume":"10","author":"Moskowitz SM","year":"2008","unstructured":"Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med. 2008, 10:851-68. 10.1097\/GIM.0b013e31818e55a2","journal-title":"Genet Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799315984","article-title":"New therapies in cystic fibrosis","volume":"18","author":"Ratjen F","year":"2012","unstructured":"Ratjen F, Grasemann H. New therapies in cystic fibrosis. Curr Pharm Des. 2012, 18:614-27. 10.2174\/138161212799315984","journal-title":"Curr Pharm Des"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00228013","article-title":"CFTR: cystic fibrosis and beyond","volume":"44","author":"Mall MA","year":"2014","unstructured":"Mall MA, Hartl D. CFTR: cystic fibrosis and beyond. Eur Respir J. 2014, 44:1042-54. 10.1183\/09031936.00228013","journal-title":"Eur Respir J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui H","year":"1998","unstructured":"Matsui H, Grubb BR, Tarran R. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell. 1998, 95:1005-15. 10.1016\/S0092-8674(00)81724-9","journal-title":"Cell"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i46.8552","article-title":"Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases","volume":"19","author":"Haack A","year":"2013","unstructured":"Haack A, Arag\u00e3o GG, Novaes MR. Pathophysiology of cystic fibrosis and drugs used in associated digestive tract diseases. World J Gastroenterol. 2013, 19:8552-61. 10.3748\/wjg.v19.i46.8552","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26625","article-title":"Impact of intrinsic and extrinsic risk factors on early-onset lung disease in cystic fibrosis","volume":"58","author":"Huang L","year":"2023","unstructured":"Huang L, Lai HJ, Song J, et al.. Impact of intrinsic and extrinsic risk factors on early-onset lung disease in cystic fibrosis. Pediatr Pulmonol. 2023, 58:3071-82. 10.1002\/ppul.26625","journal-title":"Pediatr Pulmonol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201309-303OC","article-title":"Risk factors for the progression of cystic fibrosis lung disease throughout childhood","volume":"11","author":"Sanders DB","year":"2014","unstructured":"Sanders DB, Li Z, Laxova A, et al.. Risk factors for the progression of cystic fibrosis lung disease throughout childhood. Ann Am Thorac Soc. 2014, 11:63-72. 10.1513\/AnnalsATS.201309-303OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell SC","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al.. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020, 8:65-124. 10.1016\/S2213-2600(19)30337-6","journal-title":"Lancet Respir Med"},{"key":"ref29","article-title":"Pharmacologic management of cystic fibrosis","volume":"49","author":"Hale K","year":"2024","unstructured":"Hale K, Brown S. Pharmacologic management of cystic fibrosis. US Pharm 49.7. 2024, 49:17-28.","journal-title":"US Pharm 49.7"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco M","year":"2019","unstructured":"Lopes-Pacheco M. CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2019, 10:1662. 10.3389\/fphar.2019.01662","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008512","article-title":"Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation","volume":"22","author":"Sermet-Gaudelus I","year":"2013","unstructured":"Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev. 2013, 22:66-71. 10.1183\/09059180.00008512","journal-title":"Eur Respir Rev"},{"key":"ref32","unstructured":"Dosing and Administration for KALYDECO\u00ae (ivacaftor). (2023). Accessed. December 20, 2023: http:\/\/www.kalydecohcp.com\/dosing-administration."},{"key":"ref33","unstructured":"Dosing and Administration. Orkambi (lumacaftor\/ivacaftor) product information. (2023). Accessed. December 20, 2023: https:\/\/www.orkambihcp.com\/dosing-and-administration."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-3262-2_13","article-title":"Perspectives on the common drug review process at the Canadian Agency for Drugs and Technologies in Health","author":"Lefebvre P","year":"2018","unstructured":"Lefebvre P, Lafeuille MH, Tiggelaar S. Perspectives on the common drug review process at the Canadian Agency for Drugs and Technologies in Health. Decision Making in a World of Comparative Effectiveness Research. Birnbaum H, Greenberg P (ed): Adis, Singapore, Singapore; 2018. 167-79. 10.1007\/978-981-10-3262-2_13"},{"key":"ref35","unstructured":"Dosing and Administration. Symdeko (tezacaftor\/ivacaftor) product information. (2023). Accessed. Accessed: December 20, 2023: https:\/\/www.symdekohcp.com\/dosing-and-administration."},{"key":"ref36","unstructured":"\u201cContraindications\u201d. Symdeko, Product Monograph, Vertex Pharmaceuticals (Canada) Incorporated. (2024). Accessed. August 21, 2020: https:\/\/pi.vrtx.com\/files\/Canadapm_symdeko_en.pdf."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.3.192","article-title":"Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley K","year":"2020","unstructured":"Ridley K, Condren M. Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J Pediatr Pharmacol Ther. 2020, 25:192-7. 10.5863\/1551-6776-25.3.192","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref38","unstructured":"Dosage and Administration. Highlights of prescribing information. (2021). Accessed. February 21, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf."},{"key":"ref39","unstructured":"Dosage and Administration. Highlights of prescribing information, Pulmozyme (Dornase alpha) product information. (2024). Accessed. February 21, 2024: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86."},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001506.pub4","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"9","author":"Wark P","year":"2018","unstructured":"Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018, 9:506. 10.1002\/14651858.CD001506.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4103\/2229-3485.179434","article-title":"Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: a quasi-experimental study","volume":"7","author":"Gupta HV","year":"2016","unstructured":"Gupta HV, Gupta VV, Kaur G, et al.. Effectiveness of 3% hypertonic saline nebulization in acute bronchiolitis among Indian children: a quasi-experimental study. Perspect Clin Res. 2016, 7:88-93. 10.4103\/2229-3485.179434","journal-title":"Perspect Clin Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart GZ","year":"2009","unstructured":"Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009, 135:1223-32. 10.1378\/chest.08-1421","journal-title":"Chest"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana C","year":"2006","unstructured":"Cigana C, Nicolis E, Pasetto M, Assael BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun. 2006, 350:977-82. 10.1016\/j.bbrc.2006.09.132","journal-title":"Biochem Biophys Res Commun"},{"key":"ref44","unstructured":"Dosage and Administration. Highlights of prescribing information, Tobi Podhaler (tobramycin inhalation powder) product information. (2023). Accessed. February 21, 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/201688s019lbl.pdf."},{"key":"ref45","unstructured":"Dosage and Administration. Highlights of prescribing information, Tobi (tobramycin) product information. (2023). Accessed. February 21, 2024: https:\/\/www.novartis.com\/sites\/novartis_com\/files\/novartis-20-f-2017.pdf."},{"key":"ref46","unstructured":"Dosage and Administration. Highlights of prescribing information, Cayston (aztreonam for inhalation) product information. (2019). Accessed. November 3, 2019: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/respiratory\/cayston\/cayston_pi.pdf."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2008-0155OC","article-title":"Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis","volume":"41","author":"Meyer M","year":"2009","unstructured":"Meyer M, Huaux F, Gavilanes X, et al.. Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol. 2009, 41:590-602. 10.1165\/rcmb.2008-0155OC","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20376","article-title":"Clinical scoring systems in cystic fibrosis","volume":"41","author":"Hafen GM","year":"2006","unstructured":"Hafen GM, Ranganathan SC, Robertson CF, Robinson PJ. Clinical scoring systems in cystic fibrosis. Pediatr Pulmonol. 2006, 41:602-17. 10.1002\/ppul.20376","journal-title":"Pediatr Pulmonol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.17795\/compreped-4558","article-title":"Shwachman score in clinical evaluation of cystic fibrosis","volume":"4","author":"Khalilzadeh S","year":"2013","unstructured":"Khalilzadeh S. Shwachman score in clinical evaluation of cystic fibrosis. J Compr Ped. 2013, 4:82-5. 10.17795\/compreped-4558","journal-title":"J Compr Ped"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.4.7921452","article-title":"Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis","volume":"150","author":"Arens R","year":"1994","unstructured":"Arens R, Gozal D, Omlin KJ, Vega J, Boyd KP, Keens TG, Woo MS. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med. 1994, 150:1154-7. 10.1164\/ajrccm.150.4.7921452","journal-title":"Am J Respir Crit Care Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003147.pub4","article-title":"Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis","author":"McIlwaine M","year":"2015","unstructured":"McIlwaine M, Button B, Dwan K. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev. 2015, 147. 10.1002\/14651858.CD003147.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1177\/17534666221089467","article-title":"Effectiveness of positive expiratory pressure on patients over 16 years of age with cystic fibrosis: systematic review and meta-analysis","volume":"16","author":"Rocamora-P\u00e9rez P","year":"2022","unstructured":"Rocamora-P\u00e9rez P, Benzo-Iglesias MJ, Valverde-Mart\u00ednez ML\u00c1, Garc\u00eda-Luengo AV, Aguilar-Parra JM, Trigueros R, L\u00f3pez-Liria R. Effectiveness of positive expiratory pressure on patients over 16 years of age with cystic fibrosis: systematic review and meta-analysis. Ther Adv Respir Dis. 2022, 16:801-5. 10.1177\/17534666221089467","journal-title":"Ther Adv Respir Dis"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.122663","article-title":"High frequency chest wall oscillation in cystic fibrosis","volume":"65","author":"Bradley JM","year":"2010","unstructured":"Bradley JM. High frequency chest wall oscillation in cystic fibrosis. Thorax. 2010, 65:189-90. 10.1136\/thx.2009.122663","journal-title":"Thorax"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199910)28:4<255::AID-PPUL4>3.0.CO;2-K","article-title":"Comparison of flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation","volume":"28","author":"Gondor M","year":"1999","unstructured":"Gondor M. Comparison of flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol. 1999, 28:255-60. 10.1002\/(SICI)1099-0496(199910)28:4&lt;255::AID-PPUL4&gt;3.0.CO;2-K","journal-title":"Pediatr Pulmonol"},{"key":"ref55","article-title":"Comparison of Flutter device and chest physiotherapy in the treatment of cystic fibrosis pulmonary exacerbation","volume":"26","author":"Homnick DN","year":"1998","unstructured":"Homnick DN. Comparison of Flutter device and chest physiotherapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol. 1998, 26:239-45.","journal-title":"Pediatr Pulmonol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70064-7","article-title":"Long-term comparative trial of conventional postural drainage and autogenic drainage in cystic fibrosis","volume":"36","author":"McIlwaine M","year":"2010","unstructured":"McIlwaine M. Long-term comparative trial of conventional postural drainage and autogenic drainage in cystic fibrosis. Eur Respir J. 2010, 36:1096-101. 10.1016\/S0022-3476(97)70064-7","journal-title":"Eur Respir J"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01500-y","article-title":"A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF","volume":"21","author":"Thee S","year":"2021","unstructured":"Thee S, Stahl M, Fischer R, et al.. A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulm Med. 2021, 21:131. 10.1186\/s12890-021-01500-y","journal-title":"BMC Pulm Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.98.12010143","article-title":"Effects of flutter and PEP mask physiotherapy on symptoms and lung function in children with cystic fibrosis","volume":"12","author":"van Winden CM","year":"1998","unstructured":"van Winden CM, Visser A, Hop W, Sterk PJ, Beckers S, de Jongste JC. Effects of flutter and PEP mask physiotherapy on symptoms and lung function in children with cystic fibrosis. Eur Respir J. 1998, 12:143-7. 10.1183\/09031936.98.12010143","journal-title":"Eur Respir J"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(88)80370-6","article-title":"Role of physiotherapy in cystic fibrosis: a 5-year prospective study","volume":"113","author":"Reisman JJ","year":"1988","unstructured":"Reisman JJ. Role of physiotherapy in cystic fibrosis: a 5-year prospective study. J Pediatr. 1988, 113:604-9. 10.1016\/s0022-3476(88)80370-6","journal-title":"J Pediatr"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000406","article-title":"Oral calorie supplements for cystic fibrosis","author":"Smyth R","year":"2000","unstructured":"Smyth R, Walters S. Oral calorie supplements for cystic fibrosis. Cochrane Database Syst Rev. 2000, 406. 10.1002\/14651858.CD000406","journal-title":"Cochrane Database Syst Rev"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic fibrosis related diabetes: nutrition and growth considerations","volume":"18 Suppl 2","author":"Kaminski BA","year":"2019","unstructured":"Kaminski BA, Goldsweig BK, Sidhaye A, Blackman SM, Schindler T, Moran A. Cystic fibrosis related diabetes: nutrition and growth considerations. J Cyst Fibros. 2019, 18 Suppl 2:S32-7. 10.1016\/j.jcf.2019.08.011","journal-title":"J Cyst Fibros"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2019-0484","article-title":"Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment","volume":"33","author":"Alves C","year":"2020","unstructured":"Alves C, Della-Manna T, Albuquerque CT. Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment. J Pediatr Endocrinol Metab. 2020, 33:835-43. 10.1515\/jpem-2019-0484","journal-title":"J Pediatr Endocrinol Metab"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102899","article-title":"Advances in cystic fibrosis-related diabetes: current status and future directions","volume":"17","author":"Lurquin F","year":"2023","unstructured":"Lurquin F, Buysschaert M, Preumont V. Advances in cystic fibrosis-related diabetes: current status and future directions. Diabetes Metab Syndr. 2023, 17:102899. 10.1016\/j.dsx.2023.102899","journal-title":"Diabetes Metab Syndr"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis","volume":"16","author":"Singh VK","year":"2017","unstructured":"Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017, 16:S70-8. 10.1016\/j.jcf.2017.06.011","journal-title":"J Cyst Fibros"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.08.009","article-title":"Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis","volume":"18","author":"van de Peppel IP","year":"2019","unstructured":"van de Peppel IP, Bodewes FA, Verkade HJ, Jonker JW. Bile acid homeostasis in gastrointestinal and metabolic complications of cystic fibrosis. J Cyst Fibros. 2019, 18:313-20. 10.1016\/j.jcf.2018.08.009","journal-title":"J Cyst Fibros"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman HG","year":"2019","unstructured":"Heijerman HG, McKone EF, Downey DG, et al.. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019, 394:1940-8. 10.1016\/S0140-6736(19)32597-8","journal-title":"Lancet"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010966.pub3","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern KW","year":"2020","unstructured":"Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020, 12:966. 10.1002\/14651858.CD010966.pub3","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309493-exploring-therapeutic-strategies-for-pediatric-cystic-fibrosis-an-in-depth-comparative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T10:40:41Z","timestamp":1729420841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309493-exploring-therapeutic-strategies-for-pediatric-cystic-fibrosis-an-in-depth-comparative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.71913","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,20]]}}}